Rexulti (Brexpiprazole): Indications, Dosing, Administration, and Safety Monitoring
FDA-Approved Indications
Rexulti is FDA-approved for three distinct indications: adjunctive treatment of major depressive disorder (MDD) in adults, treatment of schizophrenia in adults and adolescents ≥13 years, and treatment of agitation associated with dementia due to Alzheimer's disease. 1
- Not approved as a first-line treatment for dementia-related psychosis without agitation, and carries a black-box warning for increased mortality in elderly patients with dementia-related psychosis 1
- Not indicated for "as needed" (PRN) use in agitation associated with Alzheimer's dementia 1
- Carries a black-box warning for increased suicidal thoughts and behaviors in pediatric and young adult patients when used as an antidepressant adjunct; safety and effectiveness have not been established in pediatric patients with MDD 1
Recommended Dosing by Indication
Major Depressive Disorder (Adjunctive Treatment in Adults)
Start at 0.5 mg or 1 mg once daily, titrate to 1 mg daily, then increase to the target dose of 2 mg once daily based on clinical response and tolerability, with weekly dose increases; maximum dose is 3 mg daily. 1
- Target dose: 2 mg once daily 1
- Maximum dose: 3 mg once daily 1
- Titration interval: weekly adjustments 1
Schizophrenia in Adults
Start at 1 mg once daily on Days 1–4, increase to 2 mg daily on Days 5–7, then may increase to 4 mg on Day 8 based on clinical response and tolerability. 1
- Target dose: 2–4 mg once daily 1, 2
- Maximum dose: 4 mg once daily 1
- Initial titration is rapid (over 7 days) 1
Schizophrenia in Adolescents (13–17 Years)
Start at 0.5 mg once daily on Days 1–4, increase to 1 mg daily on Days 5–7, then increase to 2 mg on Day 8 based on clinical response; weekly dose increases of 1 mg increments thereafter. 1
- Target dose: 2–4 mg once daily 1
- Maximum dose: 4 mg once daily 1
- Long-term safety data in adolescents show 1.2% discontinuation due to adverse events over 24 months 3
Agitation Associated with Dementia Due to Alzheimer's Disease
Start at 0.5 mg once daily on Days 1–7, increase to 1 mg daily on Days 8–14, then increase to 2 mg on Day 15; may increase to maximum 3 mg daily after at least 14 days at 2 mg based on clinical response. 1
- Target dose: 2 mg once daily 1
- Maximum dose: 3 mg once daily 1
- Critical timing consideration: Brexpiprazole takes 6–12 weeks to separate from placebo in clinical trials, with greatest benefit in patients with severe agitation/aggression 4, 5
Dosage Adjustments for Special Populations
Hepatic Impairment
In patients with moderate to severe hepatic impairment (Child-Pugh score ≥7), maximum dose is 2 mg once daily for MDD or Alzheimer's agitation, and 3 mg once daily for schizophrenia. 1
Renal Impairment
In patients with creatinine clearance <60 mL/minute, maximum dose is 2 mg once daily for MDD or Alzheimer's agitation, and 3 mg once daily for schizophrenia. 1
CYP2D6 Poor Metabolizers and Drug Interactions
Dosage modifications are required for CYP2D6 poor metabolizers and when co-administered with strong CYP3A4 inhibitors, CYP2D6 inhibitors, or strong CYP3A4 inducers. 1
- When used with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) in MDD, no dosage adjustment is needed 1
- Specific adjustment tables are provided in full prescribing information for other scenarios 1
Administration Instructions
Administer Rexulti orally once daily, with or without food. 1
- Available tablet strengths: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg 1
- Once-daily dosing improves adherence 6
Safety Monitoring Considerations
Baseline Assessments Required
Before initiating Rexulti, obtain:
- Cardiovascular assessment: Blood pressure, heart rate, and ECG in patients with known cardiovascular or cerebrovascular disease 1
- Metabolic parameters: Fasting glucose or HbA1c, lipid panel, body weight, and BMI 1
- Complete blood count (CBC) in patients with pre-existing low white blood cell count or history of leukopenia/neutropenia 1
- Movement disorder screening: Document any pre-existing abnormal movements to avoid later misattribution to medication 1
Ongoing Monitoring Schedule
Metabolic Monitoring
Monitor weight, BMI, fasting glucose, and lipid panel at baseline, 3 months, and annually thereafter; weight gain is the most common adverse event requiring monitoring. 1, 2, 7
- In short-term trials, approximately 10% of patients receiving brexpiprazole 1–4 mg/day gained ≥7% body weight from baseline versus 4% on placebo (NNH = 17) 2, 7
- In adolescents, 19.8% experienced clinically meaningful weight gain after adjusting for natural growth 3
- Weight gain may be more pronounced in long-term treatment 2, 7
Hematologic Monitoring
Perform complete blood counts in patients with pre-existing low WBC or history of drug-induced leukopenia/neutropenia; discontinue if clinically significant decline in WBC occurs without other causative factors. 1
Cardiovascular Monitoring
Monitor blood pressure and heart rate regularly, especially during dose titration, due to risk of orthostatic hypotension and syncope. 1
- Particular vigilance required in patients with known cardiovascular or cerebrovascular disease, dehydration risk, or syncope history 1
Movement Disorder Monitoring
Assess for tardive dyskinesia periodically; discontinue if clinically appropriate. 1
- Akathisia rates: 5.5% for brexpiprazole 1–4 mg/day versus 4.6% for placebo in schizophrenia (NNH = 112); 8.6% in MDD trials (NNH = 15) 7
Critical Safety Warnings and Adverse Events
Black-Box Warnings
- Increased mortality in elderly patients with dementia-related psychosis: Rexulti is not approved for dementia-related psychosis without agitation associated with Alzheimer's disease 1
- Suicidal thoughts and behaviors: Close monitoring required in all antidepressant-treated patients, especially pediatric and young adults 1
Common Adverse Events by Indication
In MDD (adjunctive): Weight gain, somnolence, and akathisia (≥5% and at least twice placebo rate) 1
In schizophrenia (adults): Weight gain (≥4% and at least twice placebo rate) 1
In schizophrenia (adolescents): Extrapyramidal symptoms excluding akathisia (≥5% and at least twice placebo rate) 1, 3
In Alzheimer's agitation: Nasopharyngitis and dizziness (≥4% and at least twice placebo rate) 1
Serious Adverse Events Requiring Immediate Action
- Neuroleptic malignant syndrome: Manage with immediate discontinuation and close monitoring 1
- Seizures: Use cautiously in patients with seizure history or conditions lowering seizure threshold 1
- Pathological gambling and other compulsive behaviors: Consider dose reduction or discontinuation 1
- Cerebrovascular adverse reactions: Increased incidence of stroke and TIA in elderly patients with dementia 1
Tolerability Profile
Discontinuation rates due to adverse events are low: 3% for brexpiprazole versus 1% for placebo in MDD (NNH = 53), and lower than placebo in schizophrenia trials. 7
- Most adverse events are mild to moderate in severity 3
- Minimal effects on prolactin and no clinically relevant QTc prolongation 2, 7
- Effects on glucose and lipids are small 2, 7
Clinical Efficacy Benchmarks
Schizophrenia
Pooled responder rates: 45.5% for brexpiprazole 2–4 mg/day versus 31.0% for placebo (NNT = 7); relapse prevention NNT = 4. 2, 7
Major Depressive Disorder (Adjunctive)
Responder rates: 23.2% for brexpiprazole versus 14.5% for placebo (NNT = 12). 7
Alzheimer's Agitation
Brexpiprazole 2–3 mg/day shows efficacy with small effect sizes; greatest benefit in severe agitation/aggression, but requires 6–12 weeks to separate from placebo. 4, 5, 8
Contraindications
Known hypersensitivity to brexpiprazole or any component of the formulation. 1
Key Clinical Pearls
- Periodic reassessment is required to determine continued need and appropriate dosage 1
- Cognitive and motor impairment may occur; caution patients about operating machinery 1
- Post-marketing surveillance is critical for understanding the real-world safety profile, particularly in elderly patients with dementia 5
- Brexpiprazole may be prioritized over off-label use of other antipsychotics for Alzheimer's agitation given its FDA approval for this indication 5